1.Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-
Zhe ZHAO ; Fangyuan LI ; Jingwen NING ; Ran PENG ; Junmei SHANG ; Hui LIU ; Meiyu SHANG ; Xiu-Qi BAO ; Dan ZHANG
Acta Pharmaceutica Sinica B 2021;11(9):2859-2879
Parkinson's disease (PD) is the second most common neurodegenerative disease, but none of the current treatments for PD can halt the progress of the disease due to the limited understanding of the pathogenesis. In PD development, the communication between the brain and the gastrointestinal system influenced by gut microbiota is known as microbiota-gut-brain axis. However, the explicit mechanisms of microbiota dysbiosis in PD development have not been well elucidated yet. FLZ, a novel squamosamide derivative, has been proved to be effective in many PD models and is undergoing the phase I clinical trial to treat PD in China. Moreover, our previous pharmacokinetic study revealed that gut microbiota could regulate the absorption of FLZ
Result Analysis
Print
Save
E-mail